Clinical Trial Update: A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A master protocol Phase 1/2 trial sponsored by AstraZeneca evaluating biomarker-guided anticancer agents for advanced/recurrent ovarian cancer has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Advanced/Recurrent Ovarian Cancer | Phase 1, Phase 2 | Status: WITHDRAWN